Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May;17(5):e13150.
doi: 10.1111/irv.13150.

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England

Katie Harman  1 , Sophie Grace Nash  1 , Harriet H Webster  1 , Natalie Groves  2 , Jo Hardstaff  3 , Jessica Bridgen  3 , Paula B Blomquist  3 , Russell Hope  1 , Efejiro Ashano  4 , Richard Myers  2 , Sakib Rokadiya  5 , Susan Hopkins  6 , Colin S Brown  7 , Meera Chand  2 , Gavin Dabrera  1 , Simon Thelwall  1
Affiliations

Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with sotrovimab in the community in England

Katie Harman et al. Influenza Other Respir Viruses. 2023 May.

Abstract

There are concerns that sotrovimab has reduced efficacy at reducing hospitalisation risk against the BA.2 sub-lineage of the Omicron SARS-CoV-2 variant. We performed a retrospective cohort (n = 8850) study of individuals treated with sotrovimab in the community, with the objective of assessing whether there were any differences in risk of hospitalisation of BA.2 cases compared with BA.1. We estimated that the hazard ratio of hospital admission with a length of stay of 2 days or more was 1.17 for BA.2 compared with BA.1 (95%CI 0.74-1.86). These results suggest that the risk of hospital admission was similar between the two sub-lineages.

Keywords: COVID-19 therapeutics; SARS-CoV-2; neutralising monoclonal antibodies; severity.

PubMed Disclaimer

Conflict of interest statement

GD declares that his employer's predecessor organisation, Public Health England, received funding from GlaxoSmithKline for a research project related to influenza antiviral treatment. This preceded and had no relation to COVID‐19, and GD had no role in and received no funding from the project. All other authors report no potential conflicts.

References

    1. National Institute for Health and Care Excellence BNF . Sotrovimab. https://bnf.nice.org.uk/drug/sotrovimab.html#indicationsAndDoses. Accessed 9 May, 2022.
    1. Medicines and Healthcare products Regulatory Agency . Regulatory approval of Xevudy (sotrovimab). https://www.gov.uk/government/publications/regulatory-approval-of-xevudy.... Accessed 9 May, 2022.
    1. Martin‐Blondel G, Marcelin A‐G, Soulié C, et al. Outcome of very high‐risk patients treated by sotrovimab for mild‐to‐moderate COVID‐19 Omicron, a prospective cohort study (the ANRS 0003S COCOPREV study). J Infect. 2022;S0163‐4453(22):00196‐00197. doi:10.1016/j.jinf.2022.04.010 - DOI - PMC - PubMed
    1. Gupta A, Gonzalez‐Rojas Y, Juarez E, et al. Early treatment for Covid‐19 with SARS‐CoV‐2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941‐1950. doi:10.1056/NEJMoa2107934 - DOI - PubMed
    1. Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antiviral agents against the SARS‐CoV‐2 Omicron subvariant BA.2. N Engl J Med. 2022;386(15):1475‐1477. doi:10.1056/NEJMc2201933 - DOI - PMC - PubMed

Supplementary concepts